Invention Publication
- Patent Title: USE OF ENSARTINIB OR SALT THEREOF IN TREATMENT OF DISEASE CARRYING MET 14 EXON SKIPPING MUTATION
-
Application No.: US18682227Application Date: 2022-08-04
-
Publication No.: US20240342169A1Publication Date: 2024-10-17
- Inventor: Lijia LIU , Jing GUO , Yu WANG , Xiangdong ZHAO , Jie CHEN , Yang WANG , Xiaobin YUAN , Dong JI , Licheng KONG , Lieming DING
- Applicant: BETTA PHARMACEUTICALS CO., LTD
- Applicant Address: CN Hangzhou
- Assignee: BETTA PHARMACEUTICALS CO., LTD
- Current Assignee: BETTA PHARMACEUTICALS CO., LTD
- Current Assignee Address: CN Hangzhou
- Priority: WO TCN2021111878 2021.08.10
- International Application: PCT/CN2022/110160 2022.08.04
- Date entered country: 2024-02-08
- Main IPC: A61K31/501
- IPC: A61K31/501 ; A61P35/00
Abstract:
Embodiments of the present application provide Ensartinib or a salt thereof and a use of a composition containing Ensartinib or the salt thereof in treatment of a disease carrying MET 14 exon skipping mutation.
Public/Granted literature
- US1703097A Process for the manufacture of marble plaster Public/Granted day:1929-02-26
Information query
IPC分类:
